The limitations of EGFR mutation-targeted monotherapy in NSCLC underscore the need for combined therapeutic strategies, specifically combinatorial regimens that integrate pathway modulation and phenotypic targeting [16]. Here, EGFR is linked to non-small cell lung carcinoma.